Descrizione del progetto DEENESFRITPL Un’alternativa ai vaccini per un virus diffuso Il virus respiratorio sinciziale (RSV) ha infettato 33 milioni di persone, tra cui la maggior parte dei bambini di età inferiore a 2 anni. Tuttavia, non esiste alcun vaccino per questo virus che, ogni anno, uccide 120 000 persone. Alla ricerca di un modo per aggirare l’infezione virale, il progetto RSVTriVax ha lavorato sull’uso di immunogeni focalizzati sugli epitopi che è possibile produrre a basso costo in alternativa allo sviluppo del vaccino. TriVax incrementa gli anticorpi funzionali sotto-dominanti e le sperimentazioni su primati non umani hanno avuto successo e si sono dimostrate sicure. TriVax è rivolto alle donne in gravidanza e agli anziani, fornendo prevenzione e copertura a costi molto più bassi per la salute pubblica. Mostra l’obiettivo del progetto Nascondi l’obiettivo del progetto Obiettivo The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine. Campo scientifico natural sciencesbiological scienceszoologymammalogyprimatologymedical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesmicrobiologyvirologymedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-2019-POC - ERC Proof of Concept Grant Invito a presentare proposte ERC-2019-PoC Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot Istituzione ospitante ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE Contribution nette de l'UE € 150 000,00 Indirizzo BATIMENT CE 3316 STATION 1 1015 Lausanne Svizzera Mostra sulla mappa Regione Schweiz/Suisse/Svizzera Région lémanique Vaud Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale Nessun dato Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE Svizzera Contribution nette de l'UE € 150 000,00 Indirizzo BATIMENT CE 3316 STATION 1 1015 Lausanne Mostra sulla mappa Regione Schweiz/Suisse/Svizzera Région lémanique Vaud Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale Nessun dato
